Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- BioScrip, Inc. (NASDAQ: BIOS ) today announced ... Global Healthcare Conference to be held June 3-6, 2013 ... Richard Smith , President and Chief Executive ... Financial Officer, will present on Monday, June 3, 2013 ... About BioScrip BioScrip, Inc. provides comprehensive infusion and ...
(Date:5/23/2013)... SCHOFIELD, Wis. , May 23, 2013 /PRNewswire/ ... a researcher, developer, and marketer of over-the-counter (OTC) ... re-issued its research opinion on the company based ... Highlights , Non-Prescription, All Natural Product ... Show the Product Outperforms #1 Prescription Competitor ...
(Date:5/23/2013)... 23, 2013 VG Energy, an agricultural ... DAK Renewable Research to conduct field trials using ... Energy is a majority owned subsidiary of VG ... VG Energy,s exclusively licensed compound LipidMax selectively inhibits ... in plants, possessing a wide variety of applications ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 On April ... trips to supermarkets to search for the growing antibiotic ... aisles. Results from a year long study were released ... in foods, specifically meats, over previous years. For those ... the growth of antibiotic resistant bacteria in food, may ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Acne Cream, Probiotic Action Shares News on How Some Food may Breed Acne Causing Bacteria 2
... David B. Samadi, M.D., a world renowned urologic oncologist, discusses his ... techniques spare nerves, tissues, and organs responsible for sexual function and ... surgeries and the results are quite pleasing for his patients. ... ...
... study of Global Methylation with results in half the time ... ... ST. LOUIS, Oct. 30 Sigma-Aldrich (Nasdaq:,SIAL) today introduced ... http://www.sigma-aldrich.com/mdq1 . The,Methylated DNA Quantification Kit employs a familiar ELISA-like ...
... the National Institute of Standards and Technology ... to quickly and cheaply analyze nanoscale dimensions ... Optical Microscope (TSOM) imaging, the technique has ... and biotechnology. , Optical microscopes are not ...
Cached Biology Technology:Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 2Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 3Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast 4Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 2Sigma-Aldrich Introduces Methylated DNA Quantification Technology for Epigenetic Research 3Nanoscale dimensioning is fast, cheap with new NIST optical technique 2
(Date:5/22/2013)... and human health effects from disposal of millions ... scientists to recommend stronger government policies to encourage ... materials. That,s the conclusion of a new paper ... Technology . , Oladele A. Ogunseitan and colleagues ... for powering everything from smart phones to components ...
(Date:5/22/2013)... how climate change will affect interactions between species in ... of Animal Ecology . This knowledge, they say, is ... how species are likely to be impacted by rising ... among biologists that climate change is affecting how species ... to have very important consequences for the stability and ...
(Date:5/22/2013)... additives known as phthalates (pronounced THAL-ates) are odorless, ... in flooring, plastic cups, beach balls, plastic wrap, ... Control and Preventionthe bodies of most Americans. Once ... scrutiny. A growing collection of evidence suggests dietary ... and mix with food) may cause significant metabolic ...
Breaking Biology News(10 mins):UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2
... and likely to die of - heart disease compared ... are to blame, according to a new University of Leicester ... Maciej Tomaszewski, New Blood Lecturer in Cardiovascular Medicine in the ... that this "male disadvantage" may be related to the sex-specific ...
... an agreement was reached by the Alliance for a ... sales restrictions on "competitive foods" such as soft drinks ... say limiting the availability of soft drinks at school ... elementary school children. In a study of more ...
... Tech have used skin cells to create artificial bones ... into other tissues such as tendons or ligaments. The ... softer tissue rather than the sudden shift of previously ... and allowing them to handle weight more successfully. The ...
Cached Biology News:Sex hormones link to heart risk 2Engineers create bone that blends into tendons 2